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KEYWORDS	
	 Two	 simple,	 rapid	 and	 precise	 reversed	 phase	 liquid	 chromatographic	methods	 have	 been
developed	 and	 validated	 for	 the	 simultaneous	 determination	 of	 miconazole	 nitrate	 in	 two
binary	mixtures,	with	hydrocortisone	acetate	(Mixture	1)	and	mometasone	furoate	(Mixture
2).	For	the	two	mixtures,	chromatographic	separation	was	carried	out	on	a	C18	column.	For
mixture	 1,	 a	 mobile	 phase	 consisting	 of	 2.22	 mM	 sodium	 dihydrogen	 phosphate
(Triethylamine	 0.2%):acetonitrile	 (45:55,	 v:v)	 at	 a	 flow	 rate	 of	 0.9	 mL/min	 was	 used	 at
ambient	 temperature.	 Quantitative	 determination	 of	 miconazole	 and	 hydrocortisone	 was
achieved	with	UV	detection	at	215	and	245	nm,	respectively.	Linearity,	accuracy	and	precision
were	found	to	be	acceptable	over	the	concentration	range	of	30‐80	μg/mL	for	miconazole	and
4‐80	μg/mL	for	hydrocotisone.	For	mixture	2,	a	mobile	phase	consisting	of	acetonitrile:water
(Triethylamine	 0.2%)	 (70:30,	 v:v)	 at	 a	 flow	 rate	 of	 0.9	 mL/min	 was	 used	 at	 ambient
temperature.	Quantitative	determinations	of	miconazole	and	mometasone	were	achieved	with
UV	detection	at	215	and	250	nm,	respectively.	Linearity,	accuracy	and	precision	were	found	to
be	acceptable	over	the	concentration	range	of	10‐200	μg/mL	for	miconazole	and	2‐60	μg/mL
for	mometasone.	The	optimized	methods	were	proved	to	be	specific,	robust	and	accurate	for
the	quality	control	of	the	cited	drugs	in	pharmaceutical	preparations.	
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1.	Introduction	
	
Miconazole;	 1‐[2,4‐dichloro‐β‐(2,4‐dichlorobenzyloxy)	
phenethyl]‐imidazole	 (Scheme	 1)	 is	 an	 antifungal	 agent	 with	
similar	antimicrobial	activity	to	ketoconazole	[1].	It	is	used	for	
treatment	 of	 superficial	 candidiasis,	 skin	 infections	 dermato‐
phytosis	and	pityriasisversicolor	[1].	
Hydrocortisone;	 11β,17α,21‐trihydroxypregn‐4‐ene‐3,20‐
dione	(Scheme	1)	is	a	principal	glucocorticoid	hormone	[1,2].	It	
is	 produced	 by	 the	 adrenal	 cortex	 [2]	 and	 has	 been	 used	
clinically	 to	 treat	 skin	 problems	 such	 as	 rashes,	 eczema	 and	
others.	
Mometasone;	 9α,21‐dichloro‐11β,17‐dihydroxy‐16α‐
methylpregna‐1,4‐diene‐3,20‐dione	 (Scheme	 1)	 is	 a	 cortico‐
steroid	used	for	its	glucocorticoid	activity	[1].	
This	work	is	devoted	for	the	simultaneous	determination	of	
miconazole	in	two	binary	mixtures	which	are	available	together	
in	the	form	of	creams.	
Literature	 survey	 reveals	 that	 several	 analytical	 methods	
have	been	reported	for	the	determination	of	miconazole	nitrate	
(MIC)	 alone	 or	 in	 combinations	 including	 spectrophotometry	
[3‐11],	 spectrofluorometry	 [4]	 and	 HPLC	 [12‐30].	 Besides,	
several	 analytical	 methods	 have	 been	 reported	 for	 the	
determination	 of	 hydrocortisone	 acetate	 (HYD)	 alone	 or	 in	
combination	 with	 other	 drugs	 including	 spectrophotometry	
[31‐35],	and	HPLC	[36‐45].	MIC	and	HYD	were	simultaneously	
determined	 by	 TLC	 [46]	 and	 post	 column	 photochemical	
derivatization	HPLC	[47].	Also,	several	analytical	methods	have	
been	 reported	 for	 the	 determination	 of	 mometasone	 furoate	
(MOM)	alone	or	in	combination	with	other	drugs	by	HPLC	[48‐
52].	
	
	
	
Scheme	1	
	
Furthermore,	 literature	 survey	 reveals,	 MIC	 and	 HYD	
mixture	 was	 determined	 simultaneously	 by	 TLC	 and	 post	
column	photochemical	derivatization	HPLC	techniques	[46,47]	
which	is	tedious	and	less	applicable	in	quality	control	work.	So,	
this	 work	 can	 develop	 quality	 control	 of	 miconazole	 and	
hydrocortisone	 in	 its	 semisolid	dosage	 form	by	using	simpler,	
available	and	less	tedious	methods.	Thus,	the	aim	of	this	work	
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was	 to	 develop	 simple	 and	 validated	 HPLC	 method	 applying	
C18	 columns	 which	 are	 more	 commonly	 used.	 Besides,	 no	
previous	 method	 has	 been	 reported	 for	 the	 simultaneous	
determination	of	MIC	and	MOM.	So	such	method	was	of	interest	
using	 a	 mobile	 phase	 with	 simple	 composition	 (acetonitrile:	
water	(Triethylamine	0.2%)	(70:30,	v:v)).	So	quality	control	of	
miconazole,	 hydrocortisone	 and	 mometasone	 was	 developed	
and	sophisticated	and	that	is	one	of	the	most	important	goals	of	
my	 quality	 control	 work.	 New	 methods	 for	 simultaneous	
determination	of	two	or	more	compounds	in	 the	same	sample	
without	 previous	 chemical	 separation	 are	 always	 of	 interest.	
Due	to	wide	application	and	use	of	RP‐HPLC	technique,	the	aim	
of	 this	 study	 was	 to	 develop	 and	 validate	 an	 alternative	
reversed‐phase	 liquid	 chromatographic	 method	 for	 the	
determination	 of	 the	 binary	 mixture	 under	 investigation	
applying	C18	columns.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
A	chromatographic	system	consisting	of	Agilent	1200	series	
(CA,	USA);	interface	equipped	with	an	Agilent	quaternary	pump	
G1311A,	Agilent	UV‐visible	detector	G1314B,	an	Agilent	manual	
injector	G1328B	equipped	with	(20	µL)	injector	loop,	an	Agilent	
degasser	G1322A	and	thermo	BDS	hypersilC18	column	(5	µm,	
4.6	x	250	mm)	was	used.	An	Agilent	 syringe	of	LC	50	µL	 (CA,	
U.S.A.)	 and,	 ultrasonic	 processor;	 (Soniclean	 120T,	 220/240V,	
50/60Hz,	60W,	Thebarton	SA,	Australia)	were	also	used.	
	
2.2.	Materials	and	reagents	
	
The	pharmaceutical	 grade	MIC	was	 supplied	 and	 certified	
by	 Camlin	 Fine	 Chemicals	 (Cairo,	 Egypt)	 to	 contain	 99.70%.	
Pharmaceutical	 grade	HYD	was	supplied	and	certified	by	EVA	
Pharma	Company	(Cairo,	Egypt)	with	the	purity	of	99.85%.	The	
pharmaceutical	 grade	 MOM	 with	 the	 purity	 of	 99.80%	 and	
Mykotral	H®	 Cream	 labeled	 to	 contain	 20	mg	MIC	 and	 10	mg	
HYD	 for	 each	 1	 gram	 of	 cream	 were	 provided	 and	
manufactured	 by	 Sigma	 Pharmaceutical	 Industries	 Company	
(Cairo,	 Egypt).	 Elica	 M®	 Cream	 manufactured	 by	 Jamjom	
Pharmaceutical	Industries	Company	was	labeled	to	contain	20	
mg	 of	 MIC	 and	 1	 mg	 of	 MOM	 for	 each	 1gram	 of	 cream.	
Acetonitrile	used	was	HPLC	grade	(Scharlau,	Spain).	Bi‐distilled	
water	was	produced	 in‐house	 (Aquatron	Water	 Still,	 A4000D,	
UK).	 Membrane	 filters	 of	 0.45	 μm	 were	 purchased	 from	
Teknokroma	 (Barcelona,	 Spain).	 All	 other	 chemicals	 and	
reagents	 used	 were	 of	 analytical	 grade	 unless	 indicated	
otherwise.	
	
2.3.	Chromatographic	conditions	
	
Chromatographic	 separation	 was	 achieved	 on	 a	 thermo	
BDS	 hypercil	 C18	 column	 (5	 µm,	 4.6	 x	 250	mm)	 applying	 an	
isocratic	 elution	 based	 on	 2.22	 mM	 sodium	 dihydrogen	
phosphate:acetonitrile	 (55:45,	 v:v)	 for	 mixture	 1	 and	
acetonitrile:	water	(70:30,	v:v)	for	mixture	2	as	mobile	phases.	
Triethylamine	(0.2%)	was	added	 to	aqueous	phase	of	 the	 two	
mobile	 phases.	 The	 flow	 rate	 of	 mobile	 phase	 was	 set	 to	 0.9	
mL/min.	The	pH	of	the	mobile	phases	was	adjusted	to	3.2	using	
ortho‐phosphoric	 acid.	 The	 injection	 volume	 was	 20	 μL.	
Analyses	 were	 carried	 out	 at	 ambient	 temperature	 and	
detection	was	carried	out	at	215,	245	and	250	nm	for	MIC,	HYD	
and	MOM,	respectively.	
	
2.4.	Standard	solutions	
	
Standard	 solutions	 of	 each	 of	 MIC,	 HYD	 and	 MOM	 were	
prepared	 by	 separately	 dissolving	 20	mg	 of	 each	 drug	 in	 100	
mL	mobile	phase.	Serial	dilutions	were	prepared	to	get	1,	2,	4,	
8,	10,	20,	30,	40,	50,	60,	70,	80,	90	and	100	μg/mL	for	MIC	and	
0.5,		1,	2,	4,	8,	10,	20,	40	and	60	μg/mL	for	HYD	(Mixture	1)	and	
getting	1,	2,	4,	8,	10,	40,	80,	120,	160	and	180	μg/mL	for	MIC	
and	1,	2,	4,	8,	10,	20,	30,	40	and	60	μg/mL	for	MOM		(Mixture	
2).	
For	 mixture	 1	 further	 dilutions	 were	 made	 to	 obtain	 a	
concentration	rang	of	1‐100	μg/mL	for	MIC	and	0.5‐60.0	μg/mL	
for	HYD.	For	mixture	2	further	dilutions	were	made	to	obtain	a	
concentration	rang	of	1‐180	μg/mL	for	MIC	and	1‐60	μg/mL	for	
MOM.	
	
2.5.	Sample	preparation	
	
2.5.1.	Mixture	1		
	
One	 gram	 of	 Mykotral	 H®	 cream	was	 accurately	 weighed	
and	stirred	 in	80	mL	of	mobile	phase	with	 the	aid	of	heat	not	
exceeding	 40	 oC.	 The	 mixture	 was	 transferred	 quantitatively	
into	a	100	mL	volumetric	 flask	and	completed	to	volume	with	
the	mobile	phase.	The	mixture	was	filtered	to	obtain	a	sample	
solution	of	concentration	equivalent	to	200	μg/mL	for	MIC	and	
100	μg/mL	for	HYD.	
	
2.5.2.	Mixture	2		
	
One	gram	of	Elica	M	®	 cream	was	accurately	weighed	and	
stirred	 in	 80	 mL	 of	 mobile	 phase	 with	 the	 aid	 of	 heat	 not	
exceeding	 40	 oC.	 The	 mixture	 was	 transferred	 quantitatively	
into	a	100	mL	volumetric	 flask	and	completed	to	volume	with	
the	mobile	phase.	The	mixture	was	filtered	to	obtain	a	sample	
solution	of	concentration	equivalent	to	200	μg/mL	for	MIC.	The	
same	procedure	was	repeated	starting	with	10	g	of	 the	cream	
to	obtain	100	μg/mL	for	MOM.			
	
2.6.	Procedure	
	
2.6.1.	Linearity	and	repeatability	
	
2.6.1.1.	Mixture	1	
	
Accurately	 measured	 aliquots	 of	 working	 standard	
solutions	equivalent	 to	300‐800	μg	for	MIC	and	40‐800	μg	for	
HYD	 were	 transferred	 into	 two	 series	 of	 10	 mL	 volumetric	
flasks	 and	 completed	 to	 volume	 with	 mobile	 phase	 .The	
repeatability	 of	 the	 method	 was	 assessed	 by	 analyzing	 a	
laboratory	prepared	mixture	containing	60	µg/mL	for	MIC	and	
30	µg/mL	for	HYD.	
	
2.6.1.2.	Mixture	2		
	
Accurately	 measured	 aliquots	 of	 working	 standard	
solutions	 equivalent	 to	 100‐2000	 μg/mL	 for	MIC	 and	 20‐600	
μg/mL	 for	 MOM	 were	 transferred	 into	 two	 series	 of	 10	 mL	
volumetric	 flasks	 and	 completed	 to	 volume	 the	mobile	 phase.	
The	 repeatability	 of	 the	method	was	 assessed	 by	 analyzing	 a	
laboratory	 prepared	 mixture	 containing	 120	 µg/mL	 for	 MIC	
and	6	µg/mL	for	MOM	(n	=	6).	The	precision	(R.S.D.	%)	for	each	
compound	was	calculated.	
A	 volume	 of	 20	 µL	 of	 each	 solution	 was	 injected	 in	
triplicates	 into	 the	 chromatograph	 under	 the	 specified	
chromatographic	 conditions	 described	 previously	 [53].	 A	
calibration	curve	for	each	compound	was	obtained	by	plotting	
area	under	the	peak	(AUP)	against	concentration	(C).		
	
2.6.2.	Assay	 of	 laboratory	 prepared	mixtures,	Mykotral	H®	
and	Elica	M	®	creams	
	
2.6.2.1.	Mixture	1	
	
The	 procedure	 mentioned	 under	 Section	 2.6.1	 was	
repeated	using	laboratory	prepared	mixtures	equivalent	to	10‐
80	µg/mL	MIC	and	10‐80	µg/mL	HYD	(Figure	1).	
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Table	 1.	 Assay	 parameters	 and	 method	 validation	 obtained	 by	 applying	 HPLC	 method	 for	 the	 simultaneous	 determination	 of	 miconazole	 nitrate	 and	
hydrocortisone	acetate	or	mometasonefuroate	in	mixtures	*.	
Item	
Mixture	1														 Mixture	2
MIC	 HYD MIC MOM	
Retention	time,	min	 2.069	 5.200	 2.080	 5.700	
Wavelength	of	detection,	nm	 215	 245 215 250	
Range	of		linearity,	µg/mL	 30‐80		 4‐80 10‐200 2‐60	
Regression	equation	 y=16.4718x+48.212 y=51.1554x+6.599 y=17.1994x+29.186	 y=63.5628x+12.888
Correlation	coefficient	(r2) 0.9992	 0.9995 0.9999 0.9995	
LOD	(µg/mL)	 3.18	 1.55 2.15 1.30 
LOQ	(µg/mL)	 10.60	 5.20 7.20 4.25 
Sb	 0.233	 0.559	 0.098	 0.73	
Sa	 16.426	 30.777	 15.150	 29.800	
Confidence	limit	of	the	slope	 16.4718±270.5	 51.1554±1575.5	 17.1994±260.0	 63.5628±1894.0	
Confidence	limit	of	the	intercept	 48.2128±11.23 6.5996±3.69 29.1865±2.86 12.8888±9.40
Standard	error	of	the	estimation	 9.74	 37.44	 16.70	 34.60	
Precision,	Intra‐day	%R.S.D.	 0.97	 0.11 0.644 0.93	
Precision,	Inter‐day	%R.S.D.	 0.67	 0.73 0.76 0.35	
Precision	Drug	in	dosage	form		 100.1±1.49 100.214±1.01 100.12±1.30 100.13±1.46
Accuracy	Drug	in	laboratory	mixture	 100.9±0.78 100.4±1.30 99.54±1.05 100.4±1.20
Accuracy	Drug	added	 100.44±1.17 99.04±1.01 101.28±0.60 100.55±1.19
*	a	=	slope,	b	=	intercept,	Sb	=	standard	deviation	of	intercept,	Sa	=	standard	deviation	of	slope.	
	
Table	2.	Validation	data	for	the	proposed	method.	
Item	
Mixture	1 Mixture	2	
MIC HYD MIC	 MOM
Number	of	theoretical	plates	 5443 12876 1728	 2339
Resolution	factor	 ‐	 19.53	 ‐	 11	
Retention	time	 1.225	 1.125	 1.220	 1.300	
RSD%	of	6	injections	of	Peak	area	(cm2)	 0.970	 0.110	 0.644	 0.930	
RSD%	of	6	injections	of	Retention	time	(min)	 0.086 0.040 0.660	 0.370
	
	
Figure	1.	The	chromatogram	for	 lab	prepared	mixture	of	(a)	(MIC)	and	(b)	
(HYD)	(Mixture	1).	
	
2.6.2.2.	Mixture	2	
	
The	 procedure	 mentioned	 under	 Section	 2.6.1	 was	
repeated	using	laboratory	prepared	mixtures	equivalent	to	20‐
190	µg/mL	MIC	and	5‐60	µg/mL	MOM	(Figure	2).	
For	 the	 determination	 of	 the	 examined	 drugs	 in	Mykotral	
H®	Cream	and	Elica	M	®	Cream,	 the	sample	 solution	prepared	
under	 Section	 2.5	 was	 diluted	 to	 prepare	 different	 solutions	
equivalent	 to	 35‐80	 µg/mL	 MIC	 and	 25‐70	 µg/mL	 HYD	
(Mixture	 1)	 and	 20‐190	 µg/mL	 MIC	 and	 15‐55	 µg/mL	 MOM	
(Mixture	2)	and	injected	in	triplicate	into	the	chromatograph.	
	
3.	Results	and	discussion	
	
A	literature	survey	reveals	that	MIC	and	HYD	mixture	was	
determined	 simultaneously	 by	 TLC	 and	 post	 column	
photochemical	 derivatization	 HPLC	 techniques	 which	 are	
tedious	 and	 less	 applicable	 in	 quality	 control	work.	 Thus,	 the	
aim	 of	 this	 work	 was	 to	 develop	 simple	 and	 validated	 HPLC	
method	applying	C18	columns	which	are	more	commonly	used.	
A	 literature	 survey	 reveals	 no	 analytical	work	 to	 separate	
MIC	and	MOM	by	HPLC	techniques	so,	the	aim	of	this	work	was	
to	develop	a	new,	simple,	accurate	and	reproducible	LC	method	
for	the	simultaneous	determination	of	MIC	and	MOM	mixture	in	
a	semi‐solid	pharmaceutical	formulation.	
For	 both	 mixtures,	 statistical	 analysis	 of	 proposed	 and	
reference	 method	 reveals	 that	 no	 significant	 difference	 at	
probability	 of	 0.05.	 So,	 ensuring	 accuracy	 and	 precision	 of	
proposed	method	(Table	1).	
	
3.1.	Method	development		
	
For	 the	 separation	 of	 the	 examined	 drugs,	 various	
reversed‐phase	 C18	 columns,	 isocratic	 mobile	 phase	 systems	
were	 attempted.	 The	mobile	 phase	 composition	 and	 pH	were	
studied	and	optimized.	
	
3.1.1.	Mixture	1	
	
A	satisfactory	separation	was	obtained	with	a	mobile	phase	
composed	 of	 2.22	 mM	 sodium	 dihydrogen	 phosphate	 buffer,	
acetonitrile	 (45:55,	 v:v),	 adding	 triethylamine	 to	 the	 aqueous	
phase	 (0.2%).	 The	 mobile	 phase	 was	 adjusted	 to	 pH	 =	 3.25	
using	 ortho‐phosphoric	 acid.	 At	 higher	 acetonitrile	
concentrations,	 separation	 was	 obtained	 but	 with	 excessive	
tailing	for	HYD	peak.	At	lower	acetonitrile	concentrations,	high	
retention	 times	 for	 peaks	 were	 obtained.	 At	 pH	 =	 3.25,	
optimum	 resolution	 with	 reasonable	 retention	 times	 was	
observed	(Table	2).	
	
3.1.2.	Mixture	2	
	
A	satisfactory	separation	was	obtained	with	a	mobile	phase	
composed	 of	 acetonitrile	 and	 water	 (70:30,	 v:v)	 adding	
triethylmine	 to	 the	 aqueous	 phase	 (0.2%).	 The	 mobile	 phase	
was	adjusted	to	pH	=	3.2	using	ortho‐phosphoric	acid.	At	higher	
acetonitrile	 concentrations,	 separation	was	 obtained	 but	with	
excessive	 tailing	 for	 MOM	 peak.	 At	 lower	 acetonitrile	
concentrations,	 MOM	 peaks	 are	 resoluted	 at	 higher	 retention	
time	 so	 much	 time	 is	 consumed.	 At	 pH	 =	 3.2,	 optimum	
resolution	with	reasonable	retention	time	was	observed	(Table	
2).	
Quantitative	 determination	 based	 on	 peak	 area	 was	
achieved	with	UV	 detection	 at	 215,	 245	 and	 250	nm	 for	MIC,	
HYD	 and	 MOM	 respectively	 since	 such	 drugs	 give	 maximum	
peak	 absorbance	 at	 such	 wavelengths	 using	 UV	 scanning	
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spectrum.	 So,	 high	 sensitivity	was	 obtained	 for	 the	 separated	
drugs.	
	
Figure	2.	The	chromatogram	for	 lab	prepared	mixture	of	(a)	(MIC)	and	(b)	
(MOM)	(Mixture	2).	
	
3.2.	Validation	of	the	method	
	
3.2.1.	Linearity	
	
Linearity	 was	 studied	 for	 MIC,	 HYD	 and	 MOM.	 A	 linear	
relationship	 between	 area	 under	 the	 peak	 (AUP)	 and	
component	 concentration	 (C)	 was	 obtained.	 The	 regression	
equation	 for	 each	 drug	 was	 also	 computed	 (Table	 1)	 in	 this	
study,	 six	 concentrations	 for	 each	 compound	 were	 used.	 The	
linearity	 of	 the	 calibration	 curves	were	 validated	 by	 the	 high	
value	of	correlation	coefficients	(Table	1).	The	analytical	data	of	
the	 calibration	 curves	 including	 standard	 deviations	 for	 the	
slope	and	intercept	(Sb	and	Sa)	were	summarized	in	Table	1.	
	
3.2.2.	Accuracy	
	
Accuracy	 of	 the	 results	 was	 calculated	 by	 %	 recovery	 of	
laboratory	 prepared	mixtures	 of	 6	 different	 concentrations	 of	
the	 MIC,	 HYD	 and	 MOM	 and	 also	 by	 standard	 addition	
technique	 for	 Mykotral	 H®	 and	 Elica	 M®	 cream.	 The	 results	
obtained	 including	 the	 mean	 of	 the	 recovery	 and	 standard	
deviations	are	displayed	in	(Table	1).	
	
3.2.3.	Precision	
	
Precision	was	estimated	by	repeatability.	The	repeatability	
of	the	method	was	assessed	by	analyzing	a	mixture	containing	
60	 and	 30	 µg/mL	 for	 MIC	 and	 HYD,	 respectively	 (n	 =	 6)	
(Mixture	 1),	 and	 analyzing	 a	 mixture	 containing	 120	 and	 6	
µg/mL	for	MIC	and	MOM	(n	=	6),	respectively,	(Mixture	2).	The	
values	 of	 the	 repeatability	 (%R.S.D.)	 and	 inter‐day	 and	 intra‐
day	 precision	 (using	 three	 different	 concentrations	 in	
triplicates	 for	 three	days)	 for	 the	 three	drugs	 in	 two	methods	
are	displayed	in	Table	1.	
	
3.2.4.	Specificity	
	
Specificity	is	the	ability	of	the	analytical	method	to	measure	
the	 analyte	 response	 in	 the	 presence	 of	 interferences.	 In	 the	
present	work,	the	chromatograms	of	the	samples	were	checked	
for	 the	 appearance	 of	 any	 extra	 peaks.	 No	 chromatographic	
interference	 from	 any	 of	 the	 excipients	 was	 found	 at	 the	
retention	 times	 of	 the	 examined	 drugs.	 In	 addition,	 the	
chromatogram	of	each	drug	in	the	sample	solution	 is	 identical	
to	 the	chromatogram	received	by	 the	standard	solution	at	 the	
wavelengths	applied.	These	results	demonstrate	that	there	was	
no	 interference	 from	 other	 materials	 in	 the	 pharmaceutical	
formulations	 and	 therefore	 confirm	 the	 specificity	 of	 the	
method.	
	
3.2.5.	Range	
	
The	 calibration	 range	 was	 established	 through	
consideration	 of	 the	 practical	 range	 necessary,	 according	 to	
each	 compound	 concentration	 present	 in	 the	 pharmaceutical	
product,	 to	 give	 accurate,	 precise	 and	 linear	 results.	 The	
calibration	 range	 of	 the	 proposed	 HPLC	 method	 is	 given	 in	
Table	1.	
	
3.2.6.	Limits	of	detection	and	quantification	
	
Limit	of	detection	(LOD)	representing	the	concentration	of	
analyte	 at	 S/N	 ratio	 of	 3	 and	 limit	 of	 quantification	 (LOQ)	 at	
which	S/N	is	10	(Table	1).	According	to	ICH	recommendations	
[53],	 the	 approach	 based	 on	 the	 S.D.	 of	 the	 response	 and	 the	
slope	were	used	for	determining	the	detection	and	quantitative	
limits.	 The	 theoretical	 values	 were	 assessed	 practically	 and	
given	in	Table	1.	
	
3.2.7.	Robustness	
	
Robustness	 is	 a	measure	 of	 the	 method	 ability	 to	 remain	
unaffected	by	small	variations	in	the	method	conditions	and	is	
an	 indication	 of	 the	 method	 reliability.	 Robustness	 was	
performed	 by	 deliberately	 changing	 the	 chromatographic	
conditions.	
Variation	of	pH	of	the	mobile	phase	by	±0.2	and	its	organic	
strength	 by	 ±2%	 did	 not	 have	 any	 significant	 effect	 on	
chromatograms.	
The	 most	 important	 parameter	 to	 be	 studied	 was	 the	
resolution	 factor	 between	 the	 two	 peaks	 of	 MIC	 and	 HYD	
(Mixture	1)	and	MIC	and	MOM	(Mixture	2).	As	can	be	seen	 in	
Tables	3‐6,	good	values	of	the	resolution	factor	were	obtained	
for	 all	 these	 variations,	 indicating	 good	 robustness	 of	 the	
proposed	 LC	method.	 The	 flow	 rate	 of	 the	mobile	 phase	was	
changed	from	0.9	to	0.8	mL/min	and	1.0	mL/min.	The	organic	
strength	was	varied	by	±2%	and	pH	was	varied	by	±0.2	units.	
The	concentration	of	sodium	dihydrogen	phosphate	buffer	was	
varied	by	2%	(Mixture	1)	(Table	6).		
	
Table	3.	The	effect	of	flow	rate	of	the	mobile	phase	on	resolution	of	peaks.	
Item	
Flow	rate	(mL/min)
0.8 0.9 1.0	
Resolution	factor	MIC‐HYD 20.54	 19.52	 19.19
Resolution	factor	MIC‐MOM	 11.2	 11.24	 11.16
	
Table	4.	 Influence	of	organic	strength	of	 the	mobile	phase	on	resolution	of	
peaks.	
Concentration	vs.	organic	strength
Mixture	1	 Item,	% 55	 53 57
Resolution	factor	MIC‐HYD	 19.61	 19.87 18.42
Mixture	2	 Item,	%	 68	 70	 72	
Resolution	factor	MIC‐MOM	 11.96	 11.19 12.04
	
Table	5.	Influence	of	pH	of	the	mobile	phase	on	resolution	of	peaks.	
pH	vs.	resolution	
Mixture	1 Item,	pH 3.15 3.25 3.35
Resolution	factor	MIC‐HYD	 21.71	 20.64	 20.18	
Mixture	2 Item,	pH 3.10 	3.20 3.30
Resolution	factor	MIC‐MOM	 10.93	 10.93	 10.00	
	
Table	6.	Influence	of	concentration	of	sodium	dihydrogen	phosphate	buffer	
on	resolution	of	peaks.	
Item	(Mixture	1) 0.22	Mm	 2.22	Mm	 4.22	Mm
Resolution	factor	MIC‐HYD	 20.20	 20.15	 20.03	
	
3.3.	Statistical	analysis	of	the	results		
 
A	 statistical	 analysis	 of	 the	 results	 was	 obtained	 by	 the	
proposed	method.	The	reference	methods	were	carried	out	by	
“SPSS	statistical	package	version	11”.		
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Table	7.	Statistical	analysis	of	the	results	obtained	by	the	proposed	LC	method	and	the	reference	methods.	
Statistical	
term	
Mixture	1	 Mixture	2
MIC	 HYD	 MIC MOM	
HPLC Reference	
method	**	
HPLC Reference	
method	***	
HPLC Reference	
method	**	
HPLC	 Reference	
method	****	
Mean	 100.90	 100.20	 100.40 99.90 99.54 100.22 100.40	 100.02
S.D.	 0.780	 0.509	 1.300	 0.645	 1.052	 0.510	 1.200	 0.542	
R.S.D.	 0.770	 0.508	 1.300	 0.646	 1.056	 0.508	 1.200	 0.542	
N	 6	 6	 6	 6 6 6 6	 6	
Variance	 0.610	 0.259	 1.690	 0.416 1.100 0.260 1.440	 0.293
t‐value	 1.84	(2.228)	*	 0.85(2.228)	* 1.45	(2.228)	* 0.72(2.228)	*	
F‐value	 2.35(5.05)	*	 4.06(5.05)	* 4.26(5.05)	* 4.91(5.05)	*	
*	Figures	in	parentheses	are	the	corresponding	values	for	theoretical	t‐	and	F‐values	at	p	=	0.05.	
**	Reference	method	for	MI	using	HPLC	method	according	to	U.S.P34	[54].	
***	Reference	method	for	HY	using	UV	spectrophotometry	method	according	to	B.P.	2011	[55].	
****	Reference	method	for	MOM	using	HPLC	method	according	to	U.S.P	34	[54].	
	
	
The	significant	difference	between	groups	was	tested	by	T‐
test	 and	 F‐test	 at	 p	 =	 0.05	 as	 shown	 in	 Table	 7.	 The	 test	
ascertained	that	there	was	no	significant	difference	among	the	
methods.	
	
4.	Conclusion	
	
The	proposed	HPLC	method	provides	simple,	accurate	and	
reproducible	 quantitative	 analysis	 for	 the	 simultaneous	
determination	of	MIC	and	HYD	or	MOM	in	creams.	This	method	
was	validated	as	per	ICH	guidelines	[53].	The	proposed	method	
is	 suitable	 for	 the	 quality	 control	 determination	 of	 the	 cited	
drugs	in	ordinary	laboratories	
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